



Rule Category:
Medical

Ref: No:
2016-MN-012

Version Control:
Version No.1.0

Effective Date:
April 01st, 2017

Last Update:
October 2020

Extracorporeal Shockwave Therapy in Musculoskeletal Indications

Adjudication Guideline



Abstract

For Members

Extracorporeal shock wave therapy (ESWT) is a non-invasive treatment that involves delivery of low- or high-energy shock waves via a device to a specific site within the body. These pressure waves travel through fluid and soft tissue; their effects occur at sites where there is a change in impedance, such as the bone/soft-tissue interface. Low-energy shocks waves are applied in a series of treatments and do not typically cause any pain. High-energy shock wave treatments are generally given in one session and usually require some type of anesthesia.

ESWT should be used with caution or avoided in patients with diabetes, open growth plates, tumors, osteoporosis, rheumatoid arthritis, infection, a pacemaker, a cardiac stent, and in pregnant patients.

For Medical Professionals

There are a number of conservative treatments for handling specific musculoskeletal injuries such as: lateral epicondylitis, plantar fasciitis, calcifying tendinitis of the shoulder, Non-refractory trochanteric bursitis, including avoidance of activities with high impact, taping, casting, ice, heel cups or pads, physical therapy, exercise programs, night splints, bracing, non-steroidal anti-inflammatory drugs (NSAIDs), orthoses, shoe modifications, and steroid injections. If the mentioned above conservative treatments failed after six months, Extracorporeal Shockwave therapy (ESWT) is considered.

Approved by:
Daman

Responsible:
Medical Standards & Research

Related Adjudication Guidelines:
None

Disclaimer

By accessing these Daman Adjudication Guidelines, you acknowledge that you have read and understood the terms of use set out in the disclaimer below:

The information contained in this Adjudication Guideline is intended to outline the procedures of adjudication of medical claims as applied by the National Health Insurance Company – Daman PJSC (hereinafter "Daman"). The Adjudication Guideline is not intended to be comprehensive, should not be used as treatment guidelines and should only be used for the purpose of reference or guidance for adjudication procedures and shall not be construed as conclusive. Daman in no way interferes with the treatment of patient and will not bear any responsibility for treatment decisions interpreted through Daman Adjudication Guideline. Treatment of patient is and remains at all times the sole responsibility of the treating Healthcare Provider. This Adjudication Guideline does not grant any rights or impose obligations on Daman. The Adjudication Guideline and all of the information it contains are provided "as is" without warranties of any kind, whether express or implied which are hereby expressly disclaimed.

Under no circumstances will Daman be liable to any person or business entity for any direct, indirect, special, incidental, consequential, or other damages arising out of any use of, access to, or inability to use or access to, or reliance on this Adjudication Guideline including but without limitation to, any loss of profits, business interruption, or loss of programs or information, even if Daman has been specifically advised of the possibility of such damages. Daman also disclaims all liability for any material contained in other websites linked to Daman website.

This Adjudication Guideline is subject to the laws, decrees, circulars and regulations of Abu Dhabi and UAE. Any information provided herein is general and is not intended to replace or supersede any laws or regulations related to the Adjudication Guideline as enforced in the UAE issued by any governmental entity or regulatory authority, or any other written document governing the relationship between Daman and its contracting parties.

This Adjudication Guideline is developed by Daman and is the property of Daman and may not be copied, reproduced, distributed or displayed by any third party without Daman's express written consent. This Adjudication Guideline incorporates the Current Procedural Terminology (CPT®), which is a registered trademark of the American Medical Association ("AMA") and the CPT codes and descriptions belong to the AMA. Daman reserves the right to modify, alter, amend or obsolete the Adjudication Guideline at any time by providing one month prior notice.

Scope

This adjudication rule specifies the coverage details for medically necessary indications of Extracorporeal shockwave therapy in musculoskeletal indications as per the policy terms and conditions of each health insurance plan administered by Daman.

Adjudication Policy

Eligibility / Coverage Criteria

Daman covers Extracorporeal shockwave therapy (ESWT) for the below listed musculoskeletal indications, when pain persists for 6 months and conservative treatment failed to achieve improvement:

- Lateral epicondylitis;
- Calcaneal spur/Plantar fasciitis;
- Calcifying tendinitis of the shoulder;
- Non-refractory Trochanteric bursitis (hip).

Eligible clinician speciality
orthopaedic
Rheumatologist
Physical Medicine and Rehabilitation
Sports medicine

Requirements for Coverage

ICD and CPT codes must be coded to the highest level of specificity.

Non-Coverage

- Daman does not cover extracorporeal shock wave therapy (ESWT) for off-label indications.
- Daman does not cover extracorporeal shock wave therapy (ESWT) if documentation failed to prove that patient, meeting the diagnosis criteria, has been for six months on conservative therapy which were unsuccessfully completed.

Payment and Coding Rules

Please apply DOH payment rules and regulations and relevant coding manuals for ICD, CPT, etc.

Appendices

A. References

1. <https://www.nice.org.uk/guidance/ipg312> **(Extracorporeal shockwave therapy for refractory Achilles tendinopathy)**
2. <https://www.nice.org.uk/guidance/ipg313> **(Extracorporeal shockwave therapy for refractory tennis elbow)**
3. <https://www.nice.org.uk/guidance/ipg311> **(Extracorporeal shockwave therapy for refractory plantar fasciitis)**
4. <http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm078648.htm> **(Orthospec™ Extracorporeal Shock Wave Therapy)**
5. <http://bestpractice.bmj.com/best-practice/monograph/586/treatment/step-by-step.html> **(Rotator cuff injury)**
6. <http://bestpractice.bmj.com/best-practice/monograph/487/basics/definition.html> **(Extracorporeal shockwave therapy for refractory plantar fasciitis)**
7. https://www.uptodate.com/contents/rotator-cuff-tendinopathy?source=search_result&search=rotator+cuff+tendinopathy&selectedTitle=1%7E36 **(Rotator cuff tendinopathy)**

B. Revision History

Date	Change(s)
01-03-2017	V 1.0 Release
15-10-2020	Update: Eligible clinician speciality